HTL Hamilton Thorne Ltd

Hamilton Thorne Appoints Francesco Fragasso as CFO

Hamilton Thorne Appoints Francesco Fragasso as CFO

BEVERLY, Mass. and TORONTO, July 12, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced the appointment of Francesco Fragasso as Chief Financial Officer, effective on or about September 1, 2022. Michael Bruns will retire as CFO on that date.

“We are delighted to have Francesco join us as our CFO,” said David Wolf, President and Chief Executive Officer. “As Hamilton Thorne enters a new stage of growth, we welcome the opportunity to add individuals with operational experience at larger and more diverse organizations to our team. I look forward to working closely with Francesco as Hamilton Thorne continues growing its business.”

Mr. Fragasso currently serves as the Chief Financial Officer of Fluence Corporation (ASX:FLC), a provider of water and wastewater treatment solutions. He is responsible for all aspects of the Company’s global financial operations, reporting, accounting, treasury, administration, planning, and internal controls. Prior to joining Fluence, he served as CFO for Desalitech, a reverse osmosis technology company, where his focus included preparing the company for a sustainable growth prior to its acquisition by DuPont. He has also served as CFO and VP of Operations for Nuvera Fuel Cells, Inc. (part of Hess Corporation Group), a developer and manufacturer of multi-fuel processing systems. During his ten years at Nuvera, he held several executive positions and played a critical role in developing and implementing the company’s global strategy. Prior to Nuvera, Mr. Fragasso spent six years in public accounting and corporate finance with Deloitte.

Mr. Wolf continued, “I would like to personally thank and recognize Michael Bruns for his significant and continued contributions to Hamilton Thorne. We grew during his tenure from a niche ART equipment provider with under $7 million of revenues to one of the leaders in our field. Even though Michael is retiring as CFO, he will continue to serve the Company as a valued member of our growing finance group.”

Mr. Fragasso received his Bachelor and Master’s Degrees in Business and Finance from Universita' Bocconi, Italy, and an MBA from Boston University School of Management.

About Hamilton Thorne Ltd. ()

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at .

For more information, please contact:

David Wolf, President & CEO

Hamilton Thorne Ltd.

978-921-2050

Michael Bruns, CFO

Hamilton Thorne Ltd.

978-921-2050

Glen Akselrod

Bristol Investor Relations

905-326-1888



EN
12/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hamilton Thorne Ltd

 PRESS RELEASE

Hamilton Thorne Announces Shareholder Approval of Going Private Transa...

Hamilton Thorne Announces Shareholder Approval of Going Private Transaction BEVERLY, Mass. and TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd (TSX: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (“ART”), research, and the cell biology fields, today announced that the shareholders of the Company (the "Shareholders"), at a special meeting of Shareholders held earlier today (the "Meeting"), approved a statutory plan of arrangement (the "Transaction") under t...

 PRESS RELEASE

Hamilton Thorne Announces Mailing of Meeting Materials and Receipt of ...

Hamilton Thorne Announces Mailing of Meeting Materials and Receipt of Interim Order in Respect of Going Private Transaction BEVERLY, Mass. and TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd (TSX: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (“ART”), research, and the cell biology space, today announced the mailing of its notice of meeting, management information circular (the "Circular"), form of proxy and letter of transmittal (collectively, the "Meetin...

 PRESS RELEASE

Hamilton Thorne Reports Revenue for the Quarter and Six Months Ended J...

Hamilton Thorne Reports Revenue for the Quarter and Six Months Ended June 30, 2024, and Confirms Annual Guidance Revenue of $19.1 million and Adjusted EBITDA of $3.2 million for the quarter BEVERLY, Mass. and TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the quarter and six months ended June 30, 2024. Financial Highlights Sal...

 PRESS RELEASE

Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 202...

Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 2024 BEVERLY, Mass. and TORONTO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and six months ended June 30, 2024 before market open on Wednesday, August 14, 2024. The press release, with accompanying financial information, will be posted on the C...

 PRESS RELEASE

Hamilton Thorne Announces Agreement to be Acquired by Astorg for CAD$2...

Hamilton Thorne Announces Agreement to be Acquired by Astorg for CAD$2.25 Per Share in Cash Purchase price of CAD$2.25 per Hamilton Thorne share represents enterprise value of approximately CAD$388 million (US$282 million).Represents a premium of approximately 54% to the closing price on the Toronto Stock Exchange (“TSX”) of Hamilton Thorne shares on July 19, 2024, the last trading day prior to the announcement of the transaction, and approximately 62% to the 90-day VWAP as of the same date1.The Board of Directors of Hamilton Thorne (with interested directors abstaining) unanimously determi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch